FunctionEpoxide hydrolase (EH) converts epoxides to trans-dihydrodiols which are excreted from the body. Thus, EH acts as a detoxification agent. Epoxides are formed from degradation of aromatic compounds[1]. Bifunctional EH 2 or soluble EH (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity. Limonene-1,2-epoxide hydrolase catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol[2] .
DiseaseInhibitors of Mycobacterium tuberculosis EH such as urea derivatives, are used as anti-tuberculosis drugs. The valpromide inhibitor of EH is used as anti-epileptic drug. Soluble EH plays a role in several diseases including cardiovascular ones and is a drug target for their therapy [3].
RelevanceStructural highlights.
(PDB code 5alf).[4]
| |
3D Structures of epoxide hydrolase3D Structures of epoxide hydrolase
Updated on 10-February-2016
{"openlevels":0}
- Epoxide hydrolase
- 2e3j – EH B – Mycobacterium tuberculosis
- 1qo7, 3g02 – AnEH (mutant) – Aspergillus niger
- 2cjp – pEH I – potato
- 3cxu – pEH (mutant)
- 4i19, 4qa9 – EH – Streptomyces carzinostaticus
- Soluble epoxide hydrolase
- Epoxide hydrolase complex with inhibitor
- 3g0i – AnEH + valpromide
- 3rga – SlEH + oxazolidinone inhibitor – Streptomyces lasaliensis
- 4rzm – SlEH + lasalocid A
- Soluble epoxide hydrolase complex with inhibitor
- 1vj5, 1zd2, 1zd3, 1zd4, 1zd5, 3wk4, 4c4x, 4c4y, 4c4z, 5ai5, 5akz, 5ali – hSEH + urea derivative inhibitor
- 1cr6, 1ek1, 1ek2 – mSEH + urea derivative inhibitor
- 3otq, 3wk7, 4y2j, 4y2s, 4y2v, 5ak4, 5akh, 5aki, 5alk, 5alq, 5alv, 5aly – hSEH + pyrazole inhibitor
- 5akj, 5alf, 5als – hSEH + imidazole inhibitor
- 5akk, 5ald, 5aln, 5alo, 5alw, 5am4 – hSEH + indolone inhibitor
- 5akx, 5aky – hSEH + indazole inhibitor
- 3wk5, 3wk6, 3wk8, 3wk9, 3wkc, 5ai8, 5aic, 5akg, 5alg – hSEH + thiazole derivative inhibitor
- 3ans, 3ant – hSEH + synthetic inhibitor
- 3pdc, 5ale – hSEH catalytic domain + benzoxazole inhibitor
- 4jnc, 5alx – hSEH catalytic domain + carboxamide inhibitor
- 4x6x, 4x6y – hSEH catalytic domain + cyclopropane inhibitor
- 4hai, 3wka, 4ocz, 4od0, 5ake, 5alh, 5am1 – hSEH + piperidine derivative inhibitor
- 4y2p, 4y2q, 5ai4, 5ak5, 5ak6, 5alt, 5am5 – hSEH + pyridine derivative inhibitor
- 4y2r – hSEH + piperazine derivative inhibitor
- 5akl, 5alm, 5am0 – hSEH + pyrrolidine derivative inhibitor
- 4y2t, 5aib – hSEH + benzyloxy derivative inhibitor
- 3wkb – hSEH + quinoxaline derivative inhibitor
- 4y2u, 5ai6, 5alj, 5alr, 5am2 – hSEH + quinoline derivative inhibitor
- 4y2x, 5alu, 5alz – hSEH + adamantanyl derivative inhibitor
- 4y2y – hSEH + etylmethyamine derivative inhibitor
- 3wkd, 5alp – hSEH + morpholine derivative inhibitor
- 3wke, 5am3 – hSEH + carbamoyl derivative inhibitor
- 4j03 – hSEH + fulvestrant
- 5ai0 – hSEH + phenyl oxadiazolamine inhibitor
- 5ai9 – hSEH + phenol derivative inhibitor
- 5aia – hSEH + benzoate derivative inhibitor
- 5ak3 – hSEH + indan-amine derivative inhibitor
- 5all – hSEH + cyclohexyl methanol inhibitor
- 4o08 – BmSEH + phenoxy acetamide inhibitor
- Soluble epoxide hydrolase complex with product
- 4io0 – BmSEH + naphthyloxy propane diol
- Limonene-1,2-epoxide hydrolase
- 1nww – ReEH – Rhodococcus erythropolis
- 4r9k, 4r9l, 4xbx, 4xdw – ReEH (mutant)
- 1nu3 – ReEH + valpromide
- 4xbt, 4xdv – ReEH (mutant) + cyclohexanediol
- 4xby – ReEH (mutant) + cyclopentene oxi
ReferencesReferences
- ↑ Biswal BK, Morisseau C, Garen G, Cherney MM, Garen C, Niu C, Hammock BD, James MN. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. J Mol Biol. 2008 Sep 12;381(4):897-912. Epub 2008 Jun 17. PMID:18585390 doi:10.1016/j.jmb.2008.06.030
- ↑ Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ, de Bont JA, Jones TA, Mowbray SL. Structure of Rhodococcus erythropolis limonene-1,2-epoxide hydrolase reveals a novel active site. EMBO J. 2003 Jun 2;22(11):2583-92. PMID:12773375 doi:http://dx.doi.org/10.1093/emboj/cdg275
- ↑ Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875. PMID:19794443 doi:http://dx.doi.org/10.1038/nrd2875
- ↑ Oster L, Tapani S, Xue Y, Kack H. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today. 2015 Apr 28. pii: S1359-6446(15)00154-3. doi:, 10.1016/j.drudis.2015.04.005. PMID:25931264 doi:http://dx.doi.org/10.1016/j.drudis.2015.04.005
proteopedia link